Dementia

The main aim of this study is to investigate the effectiveness of a new drug (ANAVEX 2-73) in treating early Alzheimer’s disease. Two clinical studies investigating use of ANAXVEX 2-73 in human subjects have been completed and have shown positive outcomes in cognition, such as memory, attention, speed of processing and reasoning and problem solving.

The current study extends on previous findings to further investigate the effect of this drug (including at varying dose levels) on cognitive and functional outcomes – the former being various aspects of thinking abilities and the latter being independence in completion of daily activities.

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
Colitis and Crohn's Disease

The purpose of this research study is to compare the effects of the study drug, PF-06687234, with a placebo while also being treated with infliximab to find out which is better for treating Ulcerative Colitis (UC).

The study drug, PF-06687234 has two proteins that are connected to each other. One protein seeks out and attaches to areas of inflammation (for example the colon in UC). The second protein works to “calm down” the immune system in inflamed areas such as the colon, in UC. A placebo looks like the study drug but does not contain any active drug. Researchers use a placebo to see if the study drug works better or is safer than not taking anything.

PF-06687234 is an experimental drug which means that it is not an approved treatment for UC in Australia.

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
Dermatological Conditions

he purpose of the study is to evaluate the safety and effectiveness of the study drug tezepelumab alone, or in combination with a topical corticosteroid, in the treatment of moderate to severe atopic dermatitis. Atopic dermatitis is a chronic, inflammatory skin condition with symptoms including areas of dry, itching and reddened skin. This study will also assess the safety and effectiveness of different doses of tezepelumab.

Tezepelumab is an experimental treatment which means that it is not an approved treatment for moderate to severe atopic dermatitis in Australia. Medications, drugs and devices have to be approved for use by the Therapeutic Goods Administration in Australia.

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
Dermatological Conditions

Palmoplantar pustulosis (PPP) is a skin condition that causes blister-like sores to show up on the palms of your hands and the soles of your feet. It can also cause cracked skin or reddened, scaly patches.

CSL324 is a new biological drug, a protein called an antibody. Antibodies are usually produced by special immune cells to fight infections (bacteria, viruses or other intruders into the body). The antibody CSL324 works by blocking the activity of a growth factor called “granulocyte-colony stimulating factor” which is responsible for stimulating the bone marrow to produce white blood cells and stem cells and release them into the bloodstream. Researchers believe this antibody may be able to help decrease inflammation in many inflammatory diseases such as PPP where white blood cells have been mobilised.

CSL324 is an experimental treatment. This means that it has not been approved for treating PPP by the Therapeutic Goods Administration in Australia.

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
Dermatological Conditions

The purpose of this study is to compare the safety and effectiveness of PRN1008 as a treatment for pemphigus vulgaris (PV) and pemphigus foliaceus (PF) when taken with a corticosteroid and compare this to the safety and effectiveness of corticosteroid alone.

PRN1008 is an investigational drug developed by the study sponsor, Principia for the treatment of autoimmune and inflammatory diseases, such as pemphigus. PRN1008 is a highly selective Bruton’s tyrosine kinase (BTK) inhibitor. BTK is an enzyme that plays a crucial role in B-cell development, a type of white blood cell that is involved in the immune system, and in the white blood cells’ role in diseases like PV or PF.

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
Cancer - Liver

The main purpose of this study is to find out whether the study drug Pexa-Vec followed by standard Sorafenib treatment is better at treating your cancer than standard Sorafenib treatment alone.

Pexa-Vec is a virus that has been altered in a laboratory (genetically modified) to infect and destroy cancer cells and release a protein called GM-CSF that plays a role in the defense system fighting cancer.

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
Colitis and Crohn's Disease

The primary purpose of your participation in this study is not to treat you for your condition but to help answer the following research question: How mirikizumab compares with placebo in helping patients with UC?

Mirikizumab is an experimental treatment. This means that it is not an approved treatment for UC in Australia, by the Therapeutic Goods Administration.

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
Cancer

The ColoSTAT® test is being developed to provide an alternative option for people to undergo a colorectal cancer (CRC) screening test but for clinical, personal or cultural reasons, are unwilling or unable to use a stool test or are reluctant to undergo more invasive and costly procedures such as colonoscopy and sigmoidoscopy.

ColoSTAT® involves the collection of a blood sample, rather than stool, to assess the presence of components in the blood which, when assessed using a specifically designed algorithm, provide a CRC risk score. The algorithm uses the results from the blood test and incorporates other CRC risk factors, such as family history and lifestyle factors to determine this risk rating.

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4